

# Alla S Salasyuk

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5559815/publications.pdf>

Version: 2024-02-01

63  
papers

2,714  
citations

1162889

8  
h-index

302012

39  
g-index

68  
all docs

68  
docs citations

68  
times ranked

2956  
citing authors

#	ARTICLE	IF	CITATIONS
1	Blood pressure control, target organ protection and metabolic disorders control using a fixed combination of azilsartan medoxomil + chlorthalidone in hypertensive patients survived after severe and extremely severe COVID-19. Arterial Hypertension (Russian Federation), 2022, 27, 642-652.	0.1	0
2	Pharmacoepidemiological analysis of routine management of heart failure patients in the Russian Federation. Part II. Russian Journal of Cardiology, 2022, 27, 4759.	0.4	3
3	Optimization of blood pressure control, organ protection and metabolic disorders using a fixed-dose combination of lisinopril+amlodipine+rosuvastatin in hypertensive patients after COVID-19. Russian Journal of Cardiology, 2022, 26, 4766.	0.4	2
4	Approaches to the therapy of heart failure with reduced ejection fraction. Resolution of an online meeting of the Volga Federal District experts. Russian Journal of Cardiology, 2022, 26, 4791.	0.4	1
5	Pharmacoeconomic analysis of ferric carboxymaltose in patients with chronic heart failure and iron deficiency in the Russian Federation. , 2022, , 30-43.		0
6	Cost-effectiveness analysis of active psoriatic arthritis treatment with ixekizumab in adult patients in Russian Federation health care system. Sovremennaya Revmatologiya, 2021, 15, 119-127.	0.1	0
7	Evaluation of the economic effect of biological therapy in patients with severe COVID-19 and cytokine storm. Farmakoekonomika, 2021, 13, 377-387.	0.4	3
8	INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES". Obesity and Metabolism, 2021, 18, 5-99.	0.4	49
9	Early vascular aging in patients with metabolic syndrome: features of the course and diagnosis. Æno-Rossijskij Åurnal TerapevtiÅeskoj Praktiki, 2021, 2, 50-62.	0.1	1
10	Pharmacoepidemiological analysis of routine management of heart failure patients in the Russian Federation. Part I. Russian Journal of Cardiology, 2021, 26, 4368.	0.4	10
11	Resolution of an online meeting of the Siberian, Far Eastern and Southern Federal Districts experts on the results of the EMPEROR-Reduced trial ÆTherapeutic approaches in heart failure with reduced ejection fraction: the EMPA-REG OUTCOME trial and the EMPEROR-Reduced trialÆ. Complex Issues of Cardiovascular Diseases, 2021, 10, 121-129.	0.3	0
12	Identifying Early Vascular Ageing in Patients With Metabolic Syndrome: Unresolved Issues and a Proposed Novel VAMets Score. Heart Lung and Circulation, 2021, 30, 1752-1761.	0.2	4
13	Budget impact analysis of ertugliflozin in patients with type 2 diabetes mellitus who failed to achieve glycemic targets on metformin. ÅndokrinologijÅ Novosti, MneniÅ¢, ObuÅenie, 2021, 10, 33-43.	0.0	0
14	Pharmacoeconomic analysis of acalabrutinib in patients with chronic lymphocytic leukemia. Journal of Modern Oncology, 2021, 23, 612-620.	0.1	1
15	Clinical and economic analysis of using dapagliflozin in patients with chronic kidney disease in the Russian Federation. Consilium Medicum, 2021, 23, 932-938.	0.1	0
16	The effect of various classes of glucose-lowering medications on the blood vessel elasticity in patients with type 2 diabetes. Russian Journal of Cardiology, 2020, 25, 3766.	0.4	3
17	Azilsartan medoxomil for improving insulin resistance and adipokine levels in hypertension in comparison with angiotensin-converting enzyme inhibitors. Russian Journal of Cardiology, 2020, 25, 3767.	0.4	1
18	Pharmacoeconomic research of using aflibercept in patients with the wet age-related macular degeneration. Rossiiskii Oftal'mologicheskii Zhurnal, 2020, 13, 42-50.	0.1	2

#	ARTICLE	IF	CITATIONS
19	Pharmacoeconomic analysis of tiotropium bromide and olodaterol fixed combination as maintenance therapy for patients with COPD in the Russian Federation. <i>Farmakoeconomika</i> , 2020, 13, 101-111.	0.4	0
20	Optimal Organ Protection and Blood Pressure Control with the Single Pill Combination Lisinopril, Amlodipine and Indapamide in Arterial Hypertension. <i>Rational Pharmacotherapy in Cardiology</i> , 2020, 16, 931-937.	0.3	1
21	Pharmacoeconomic analysis of the use of dapagliflozin in patients with NYHA class II-IV chronic heart failure with reduced left ventricular ejection fraction $\leq 40\%$ in the Russian Federation. <i>Consilium Medicum</i> , 2020, 22, 45-51.	0.1	4
22	Clinical and economic aspects of bulevirtide use in patients with chronic hepatitis D. <i>Infektsionnye Bolezni</i> , 2020, 18, 104-111.	0.2	1
23	Early vascular aging risk assessment in patients with metabolic syndrome. <i>European Heart Journal</i> , 2020, 41, .	1.0	0
24	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. <i>Lancet</i> , The, 2019, 394, 121-130.	6.3	1,625
25	Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. <i>Lancet</i> , The, 2019, 394, 131-138.	6.3	394
26	PRS4 HEALTH TECHNOLOGY ASSESSMENT OF DUPILUMAB IN SEVERE BRONCHIAL ASTHMA IN THE RUSSIAN FEDERATION. <i>Value in Health Regional Issues</i> , 2019, 19, S77.	0.5	0
27	Effectiveness of insulin resistance correction and the adipokines level reduction in patients with arterial hypertension in comparison with other ARBs. <i>Russian Journal of Cardiology</i> , 2019, , 70-79.	0.4	10
28	Pharmacoeconomic rationale for alirocumab administration in acute coronary syndrome. <i>Military Thought</i> , 2019, 28, 99-104.	0.1	1
29	Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria. <i>Farmakoeconomika</i> , 2019, 12, 72-84.	0.4	2
30	Pharmacoeconomic analysis of the anidulafungin (EraxisR) in adult patients with invasive candidiasis. <i>Oncogematologiya</i> , 2019, 14, 98-108.	0.1	0
31	PRM101 - THE COST BURDEN OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION IN RUSSIAN FEDERATION. <i>Value in Health</i> , 2018, 21, S373.	0.1	0
32	OPTIMAL ORGAN PROTECTION, CONTROL OF BLOOD PRESSURE AND METABOLIC DISORDER WITH THE FIXED COMBINATION OF LISINAPRIL, AMLODIPINE AND ROSUVASTATIN IN SYSTEMIC HYPERTENSION. <i>Russian Journal of Cardiology</i> , 2018, , 49-55.	0.3	7
33	ADDITIONAL ANGIOPROTECTION AND METABOLIC DISORDERS CORRECTION IN TREATMENT OF ARTERIAL HYPERTENSION PATIENTS ARE REACHED TARGET BLOOD PRESSURE LEVELS, WITH FIXED COMBINATION OF PERINDOPRIL AND INDAPAMIDE. <i>Russian Journal of Cardiology</i> , 2018, , 67-74.	0.4	1
34	Metabolic syndrome and kidney: nephroprotection and reduction of cardiovascular risk. <i>Arterial Hypertension (Russian Federation)</i> , 2018, 24, 369-378.	0.1	2
35	Optimization of Blood Pressure Control, Metabolic Parameters, and Target Organs Protection with Perindopril + Indapamide Fixed Combination in Hypertensive Patients with Obesity and Prediabetes. <i>Diabetes</i> , 2018, 67, 129-LB.	0.3	1
36	Improving blood pressure control, organoprotection and metabolic disorders correction in patients with hypertension switching from diuretic-based combinations to fixed combination lisinopril + amlodipine + rosuvastatin. <i>Systemic Hypertension</i> , 2018, 15, 24-31.	0.1	3



#	ARTICLE	IF	CITATIONS
55	Losartan versus Telmisartan in Overweight Patients with Arterial Hypertension. Journal of Advanced Clinical Pharmacology, 2015, 2, 1-7.	0.5	1
56	Randomized Trial of Perindopril, Enalapril, Losartan and Telmisartan in Overweight or Obese Patients with Hypertension. Clinical Drug Investigation, 2013, 33, 553-561.	1.1	52
57	COMPARATIVE EFFECTIVENESS OF FIXED-DOSE COMBINATIONS OF LISINAPRIL/AMLODIPINE AND ENALAPRIL/HYDROCHLOROTHIAZIDE. Cardiovascular Therapy and Prevention (Russian Federation), 2013, 12, 25-29.	0.4	2
58	Effect of angiotensin II receptor antagonists on left ventricular hypertrophy, vascular elasticity, and lipid and carbohydrate metabolic parameters in metabolic syndrome. Systemic Hypertension, 2013, 10, 27-33.	0.1	1
59	Comparative analysis of the efficiency of the selective b-blocker nebivolol and the angiotensin II receptor blocker valsartan in men with hypertension, metabolic syndrome, and erectile dysfunction. Cardiosomatics, 2013, 4, 57-66.	0.2	0
60	Self-management of diabetes. Cardiosomatics, 2013, 4, 17-20.	0.2	0
61	Sravnitel'naya effektivnost' perindopriila A i telmisartana u patsientov s arterial'noy gipertenziey i ozhireniem. Systemic Hypertension, 2012, 9, 33-39.	0.1	0
62	The abilities of losartan in angioprotection in hypertensive patients with hyperuricemia. Systemic Hypertension, 2012, 9, 16-21.	0.1	0
63	Improving the efficacy of antihypertensive therapy with the use of fixed-dose combination therapy. Arterial Hypertension (Russian Federation), 2011, 17, 513-517.	0.1	0